2018 Volume 64 Issue 3 Pages 77-86
The definitive diagnosis of vertebrobasilar insufficiency (VBI) at ear, nose and throat clinics is difficult. In addition, there is no established treatment policy for VBI at present. Therefore, VBI is generally diagnosed based on the "Diagnosis from Medical History" of "Materials for Standardization of Vertigo Diagnosis" prepared by the Japan Society For Equilibrium Research, with severity scoring (VBI score) performed. In the present study, treatment was administered orally to three groups A (ATP + dilazep hydrochloride), B (ATP + ibudilast) and C (ATP + dilazep hydrochloride + ibudilast). All three groups showed no significant differences in the VBI score obtained at the initial diagnosis. While the presence of significant differences in the improvement of the VBI score varied among the groups, both from treatment initiation to two weeks later and from two weeks later to four weeks later, all three groups showed a trend toward an improvement in the VBI score. Only in Group C, where 3 agents were used, did the VBI score improve significantly both from the initial diagnosis to two weeks later and from two weeks later to four weeks later. Statistical analyses of the VBI score and DHI score obtained at the initial diagnosis, after two weeks and after four weeks among the three groups revealed no significant differences between each pair of groups. However, in Group C, where three agents were used, although the DHI score showed no significant improvement from the initial diagnosis to two weeks later and from two weeks later to four weeks later, the VBI score, which focused on specific symptoms in VBI, improved significantly both from treatment initiation to two weeks later and from two weeks later to four weeks later. Therefore, the regimen given to Group C was considered to be the most appropriate treatment for VBI.
